Tula oncology clinic will buy more than 10 thousand tablets of olaparib

The Tula Regional Clinical Oncology Dispensary is preparing the purchase of an expensive antitumor drug olaparib. For these purposes, the institution will allocate 28.12 million rubles.

According to the description of the procurement object, the institution plans to receive 10 thousand 080 tablets with a dosage of 150 milligrams.

Delivery is designed for the entire period of the contract - until October 31, 2027. The drug will be delivered in separate batches within ten days after the application, but not more than once every two weeks; by agreement, a one-time supply of the entire volume is possible. Delivery falls on the supplier, loading works - also at his expense.

Olaparib is a targeted drug, the first in the class of PARP inhibitors. It is used in tumors with mutations in the BRCA1/2 genes and other defects in DNA repair, primarily in ovarian, breast, pancreatic and prostate cancer. For the treatment of ovarian cancer, olaparib is the only PARP-inhibitors available in Russia under preferential provision; the drug is taken orally in the form of tablets.

The document imposes strict conditions on the quality of the goods: delivery - only in whole packages, the drug must be registered in the prescribed manner, and the residual shelf life at the time of delivery - at least 8 months (with a shelf life of 12 months) and at least 12 months for drugs with a longer shelf life.

Recall, as previously wrote “MK in Tula”, the Tula Ministry of Health spent on the purchase of this drug last year almost 100 million rubles.